The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
The company has raised US$4.5 million in funding for its AI operating system
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The companies plan to start a pivotal Phase 3 trial in the coming months
Subscribe To Our Newsletter & Stay Updated
